Incytevs.Vertex Pharmaceuticals
INCY vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 5.5× larger than Incyte by market cap; Incyte trades at the lower P/E (15.1 vs 30.7); year to date, Incyte leads (+29.6% vs +20.8%).
Side by side
| INCY | VRTX | |
|---|---|---|
| Market cap | $24.4B | $135B |
| Price | $129.72 | $552.85 |
| Today | +1.4% | +1.0% |
| Return YTD | +29.6% | +20.8% |
| Return 1Y | +50.5% | +38.6% |
| P/E | 15.1 | 30.7 |
| P/S | 4.2 | 10.7 |
| P/B | 3.8 | 6.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More INCY & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where INCY and VRTX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →